TÌNH HÌNH KIỂM SOÁT NỒNG ĐỘ NON HDL-C HUYẾT THANH Ở BỆNH NHÂN HỘI CHỨNG VÀNH CẤP KHI ĐƠN TRỊ ATORVASTATIN 40MG TẠI BỆNH VIỆN ĐA KHOA TỈNH BÌNH THUẬN NĂM 2024-2025

Abstract

Background: Elevated serum non-HDL cholesterol (non-HDL-C) levels are associated with poor outcomes in patients with acute coronary syndrome (ACS). Whether atorvastatin 40 mg monotherapy effectively controls non-HDL-C levels in the short term remains unclear, as current data are inconsistent, particularly in Vietnam. Objectives: To determine the rate of achieving target serum non-HDL-C levels in ACS patients receiving atorvastatin 40 mg monotherapy. Materials and methods: A non-controlled interventional study was conducted on 34 ACS patients treated with atorvastatin 40 mg for 4 weeks at Binh Thuan General Hospital from September 2024 to March 2025. Results: The female-to-male ratio was approximately 1.27, with a mean age of 73.18 ± 9.15 years. The mean body mass index (BMI) was 24.41 ± 2.37 kg/m², and obesity was observed in 55.9% of patients. Among comorbidities, diabetes mellitus was present in 55.9% of cases. Regarding lipid profile changes post-intervention, the mean total cholesterol level was 4.98 ± 1.67 mmol/L, and the mean HDL-C level was 1.14 ± 0.32 mmol/L. The mean non-HDL-C level remained high at 3.84 ± 1.64 mmol/L. Only 26.5% of patients achieved target non-HDL-C levels after 4 weeks of atorvastatin 40 mg monotherapy. Conclusion: Serum non-HDL-C levels remained elevated in ACS patients. Monotherapy with atorvastatin 40 mg was not highly effective in achieving non-HDL-C control.